Provided by Tiger Trade Technology Pte. Ltd.

Health Care Select Sector SPDR Fund

168.81
+1.721.03%
Pre-market: 168.950.1400+0.08%08:57 EDT
Volume:8.88M
Turnover:1.50B
Market Cap:43.56B
PE:-11.87
High:170.38
Open:167.87
Low:167.43
Close:167.09
52wk High:176.60
52wk Low:141.05
Shares:258.02M
Float Shares:258.02M
Volume Ratio:1.01
T/O Rate:3.44%
Dividend:2.55
Dividend Rate:1.51%
EPS(TTM):-14.2170
EPS(LYR):-14.2170
ROE:-9.22%
ROA:1.03%
PB:1.27
PE(LYR):-11.87

Loading ...

Halozyme Therapeutics Shares up 2% After Court Win Against Merck to Block Subcutaneous Keytruda in Select Markets

THOMSON REUTERS
·
Yesterday

Sector Update: Healthcare Stocks Flat to Higher Pre-Bell Wednesday

MT Newswires Live
·
Yesterday

Micro-Cap Stock Veraxa Biotech is Down 96% This Year. Can Next-Gen Drug Testing Save It?

Dow Jones
·
Yesterday

Morgan Stanley Adjusts Price Target on Merck to $177 From $179

MT Newswires Live
·
Yesterday

AbbVie’s telisotuzumab adizutecan gets two FDA Breakthrough Therapy Designations

TIPRANKS
·
Yesterday

Tempus AI announces multi-year collaboration with Moderna, Merck

TIPRANKS
·
Yesterday

Halozyme announces Dutch court of the Hague found Merck infringed patents

TIPRANKS
·
Yesterday

AbbVie Says FDA Grants Breakthrough Therapy Status for ABBV-400 in Metastatic Colorectal Cancer

Reuters
·
Yesterday

Tempus Expands Multi-Year Collaboration with Moderna, Merck on V940 Melanoma Vaccine Commercialization Support

Reuters
·
Yesterday

Analysts Conflicted on These Healthcare Names: BridgeBio Pharma (BBIO) and Vaxcyte (PCVX)

TIPRANKS
·
Yesterday

Abbvie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations from the U.S. FDA for Crc and Nsclc

THOMSON REUTERS
·
Yesterday

Halozyme Therapeutics - Iv Version of Keytruda Remains Available and not Covered by Halozyme's Patent or Court Injunction

THOMSON REUTERS
·
Yesterday

Halozyme Therapeutics - Court Rejects Merck's Arguments That Ep622 Patent is Invalid

THOMSON REUTERS
·
Yesterday

Halozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda Sc in Multiple European Markets

THOMSON REUTERS
·
Yesterday

Halozyme Therapeutics - Court Orders Msd BV to Stop Keytruda Sc Manufacture and Sale in Eight European Countries

THOMSON REUTERS
·
Yesterday

Halozyme Therapeutics - Injunction Forbids Msd from Facilitating Infringement by Affiliates

THOMSON REUTERS
·
Yesterday

Tempus Announces Multi-Year Collaboration with Moderna and Merck

THOMSON REUTERS
·
Yesterday

Morgan Stanley Adjusts Price Target on Eli Lilly to $1,430 From $1,419

MT Newswires Live
·
Yesterday

3 Australian Healthcare Stocks With Earnings Growth Over 22%

Simply Wall St.
·
Yesterday

J.P. Morgan Remains a Buy on Gilead Sciences (GILD)

TIPRANKS
·
Yesterday